Amarin Corporation plc (AMRN)
NASDAQ: AMRN · IEX Real-Time Price · USD
0.875
+0.015 (1.72%)
At close: Apr 26, 2024, 4:00 PM
0.897
+0.022 (2.55%)
After-hours: Apr 26, 2024, 6:46 PM EDT
Amarin Corporation Revenue
In the year 2023, Amarin Corporation had annual revenue of $306.91M, a decrease of -16.87%. Revenue in the quarter ending December 31, 2023 was $74.71M, a -17.21% decrease year-over-year.
Revenue (ttm)
$306.91M
Revenue Growth
-16.87%
P/S Ratio
1.17
Revenue / Employee
$1,116,040
Employees
275
Market Cap
357.68M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 306.91M | -62.28M | -16.87% |
Dec 31, 2022 | 369.19M | -213.99M | -36.69% |
Dec 31, 2021 | 583.19M | -30.87M | -5.03% |
Dec 31, 2020 | 614.06M | 184.31M | 42.89% |
Dec 31, 2019 | 429.76M | 200.54M | 87.49% |
Dec 31, 2018 | 229.21M | 48.11M | 26.56% |
Dec 31, 2017 | 181.10M | 51.02M | 39.22% |
Dec 31, 2016 | 130.08M | 48.33M | 59.11% |
Dec 31, 2015 | 81.76M | 27.55M | 50.84% |
Dec 31, 2014 | 54.20M | 27.85M | 105.69% |
Dec 31, 2013 | 26.35M | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Health Catalyst | 295.94M |
Revance Therapeutics | 234.04M |
Zynex | 184.32M |
Heron Therapeutics | 127.04M |
ADC Therapeutics | 69.56M |
Aquestive Therapeutics | 50.58M |
Mersana Therapeutics | 36.86M |
Precigen | 6.23M |
AMRN News
- 4 days ago - Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event - GlobeNewsWire
- 6 days ago - Amarin Announces Results of Annual General Meeting of Shareholders - GlobeNewsWire
- 13 days ago - Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 - GlobeNewsWire
- 20 days ago - Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 - GlobeNewsWire
- 21 days ago - New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups - GlobeNewsWire
- 25 days ago - Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe - GlobeNewsWire
- 4 weeks ago - Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo - GlobeNewsWire
- 2 months ago - Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire